Ji Luo

Ji Luo

Auto-generated profile, based on publicly available information

Ji Luo

Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in Seminars in Oncology
Verified
Journal Article
Closed access
JLJi Luo
Ji Luo

1 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CLChih-Shia Lee
Chih-Shia Lee
LLLiam C. Lee
Liam C. Lee
TYTina L. Yuan
Tina L. Yuan
SCSirisha Chakka
Sirisha Chakka
CFChristof Fellmann
Christof Fellmann
JLJi Luo
Ji Luo
Significance: Currently, there is no effective targeted therapy for oncogenic KRAS -driven cancer. We set out to identify RAS effector and stress response genes that critically support KRAS addiction, and therefore could serve as potential targets for KRAS mutant cancer. Using a combinatorial siRNA platform, we systematically interrogated the patterns of oncoeffector dependency in KRAS mutant and WT colorectal and pancreatic cancer cell lines and in normal cell lines. We found that RAF kinases are the major KRAS oncoeffectors and that cotargeting BRAF and CRAF kinases together with the autophagy E1 ligase ATG7 could efficiently eliminate KRAS mutant cells while minimizing toxicity in normal cells. Our work thus establishes a framework for the rational selection of target combinations for cancer treatment.

30 September 2014 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
TYTina L. Yuan
Tina L. Yuan
CFChristof Fellmann
Christof Fellmann
CLChih-Shia Lee
Chih-Shia Lee
CRCayde D. Ritchie
Cayde D. Ritchie
VTVishal Thapar
Vishal Thapar
SLScott W. Lowe
Scott W. Lowe
RNAi is a powerful tool for target identification and can lead to novel therapies for pharmacologically intractable targets such as KRAS. RNAi therapy must combine potent siRNA payloads with reliable in vivo delivery for efficient target inhibition. We used a functional “Sensor” assay to establish a library of potent siRNAs against RAS pathway genes and to show that they efficiently suppress their targets at low dose. This reduces off-target effects and enables combination gene knockdown. We administered Sensor siRNAs in vitro and in vivo and validated the delivery of KRAS siRNA alone and siRNA targeting the complete RAF effector node (A/B/CRAF) as promising strategies to treat KRAS-mutant colorectal cancer. We further demonstrate that improved therapeutic efficacy is achieved by formulating siRNA payloads that combine both single-gene siRNA and node-targeted siRNAs (KRAS + PIK3CA/B). The customizable nature of Sensor siRNA payloads offers a universal platform for the combination target identification and development of RNAi therapeutics. Significance: To advance RNAi therapy for KRAS-mutant cancer, we developed a validated siRNA library against RAS pathway genes that enables combination gene silencing. Using an in vivo model for real-time siRNA delivery tracking, we show that siRNA-mediated inhibition of KRAS as well as RAF or PI3K combinations can impair KRAS-mutant colorectal cancer in xenograft models. Cancer Discov; 4(10); 1182–97. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 1103

25 September 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
GYGarmen Yuen
Garmen Yuen
FKFehad J. Khan
Fehad J. Khan
SGShaojian Gao
Shaojian Gao
JSJayne M. Stommel
Jayne M. Stommel
EBEric Batchelor
Eric Batchelor
JLJi Luo
Ji Luo
CRISPR/Cas9 is a powerful gene editing tool for gene knockout studies and functional genomic screens. Successful implementation of CRISPR often requires Cas9 to elicit efficient target knockout in a population of cells. In this study, we investigated the role of several key factors, including variation in target copy number, inherent potency of sgRNA guides, and expression level of Cas9 and sgRNA, in determining CRISPR knockout efficiency. Using isogenic, clonal cell lines with variable copy numbers of an EGFP transgene, we discovered that CRISPR knockout is relatively insensitive to target copy number, but is highly dependent on the potency of the sgRNA guide sequence. Kinetic analysis revealed that most target mutation occurs between 5 and 10 days following Cas9/sgRNA transduction, while sgRNAs with different potencies differ by their knockout time course and by their terminal-phase knockout efficiency. We showed that prolonged, low level expression of Cas9 and sgRNA often fails to elicit target mutation, particularly if the potency of the sgRNA is also low. Our findings provide new insights into the behavior of CRISPR/Cas9 in mammalian cells that could be used for future improvement of this platform.

24 March 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BYBing Yu
Bing Yu
SSStephen Swatkoski
Stephen Swatkoski
AHAlesia Holly
Alesia Holly
LLLiam C. Lee
Liam C. Lee
VGValentin Giroux
Valentin Giroux
JLJi Luo
Ji Luo
Significance: Currently there are no targeted therapies for KRAS mutant cancer. Our study uncovers a critical role of the small ubiquitin-like modifier (SUMO) E2 ligase Ubc9 in sustaining the transformation growth of KRAS mutant colorectal cancer cells, thus establishing a functional link between the SUMO pathway and the KRAS oncogene. SUMO ligases are poorly explored drug targets; our work suggests that targeting the SUMO pathway, and Ubc9 in particular, could be potentially useful for the treatment of KRAS mutant colorectal cancers.

28 September 2013 in Protein & Cell
Verified
Journal Article
Closed access
PDF file
MWMeng-Tzu Weng
Meng-Tzu Weng
JLJi Luo
Ji Luo
Enhancer of rudimentary homolog (ERH) is a small, highly conserved protein among eukaryotes. Since its discovery nearly 20 years ago, its molecular function has remained enigmatic. It has been implicated to play a role in transcriptional regulation and in cell cycle. We recently showed that ERH binds to the Sm complex and is required for the mRNA splicing of the mitotic motor protein CENP-E. Furthermore, cancer cells driven by mutations in the KRAS oncogene are particularly sensitive to RNAi-mediated suppression of ERH function, and ERH expression is inversely correlated with survival in colorectal cancer patients whose tumors harbor KRAS mutation. These recent findings indicate that ERH plays an important role in cell cycle through its mRNA splicing activity and is critically required for genomic stability and cancer cell survival.